Oral contraceptives recalled

Article

An immediate voluntary recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets?about 1 million packets?was issued on February 1 by Pfizer after an internal investigation reported that some of the blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence, increasing the risk of an unintended pregnancy among women using the pills for contraception.

An immediate voluntary recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets-about 1 million packets-was issued on February 1 by Pfizer after an internal investigation reported that some of the blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence, increasing the risk of an unintended pregnancy among women using the pills for contraception.

Pfizer notified the US Food and Drug Administration, healthcare providers, and consumers of the recall on February 1.

Akrimax Pharmaceuticals distributed the product to warehouses, clinics, and retail pharmacies throughout the United States. The pills are sold in packs containing 21 tablets of active ingredients and 7 tablets with inactive ingredients. Expiration dates printed on the affected lots are from July 31, 2013 through March 31, 2014.

A complete list of lot numbers for the branded and generic formulations is posted at http://www.fda.gov/Safety/Recalls/ucm289770.htm. FDA and Pfizer advise women who have packets of pills in the affected lots to notify their physicians, return the product to the pharmacy, and begin using a second form of birth control immediately.

Read other articles in this issue of Special Delivery.

Related Videos
Understanding combined oral contraceptives and breast cancer risk | Image Credit: health.ucdavis.edu
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Enhancing cervical cancer management with dual stain | Image Credit: linkedin.com
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit: rmanetwork.com
Understanding the impact of STIs on young adults | Image Credit: providers.ucsd.edu.
CDC estimates of maternal mortality found overestimated | Image Credit: rwjms.rutgers.edu.
Study unveils maternal mortality tracking trends | Image Credit: obhg.com
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit: hyperemesis.org
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
© 2024 MJH Life Sciences

All rights reserved.